US › Healthcare

Personalis Inc (PSNL)

US · Healthcare · Diagnostics & Research

$13.52+2.42%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$15.5M
Revenue YoY
-24.9%
Net profit
$-30.0M
Profit YoY
-90.7%
EPS
$-0.29
EPS estimate
$-0.28
Net margin
-194.1%

EPS came in at -0.29 against a street estimate of -0.28 — a miss of 3.6%.

Key statistics

Market cap
$1.35B
Forward P/E
0.0
P/B
5.30
Book value
$2.43
EPS (TTM)
$-1.02
52-week high
$16.39
52-week low
$3.84
50-day MA
$11.86
200-day MA
$9.05
Beta
2.24

Analyst view

Analysts rate Personalis Inc a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $13.88.

Shareholding

Insiders
26.16%
Institutions
67.03%

Largest institutional holders

FundStake
Merck & Co Inc13.41%
Lightspeed Management Co LLC7.79%
ARK Investment Management LLC7.59%
Ameriprise Financial Inc7.25%
BlackRock Inc5.15%
T. Rowe Price Investment Management,Inc.4.54%
Aberdeen Group PLC3.33%
Vanguard Group Inc3.11%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Personalis Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.